Cambridge Trust Co. Sells 129 Shares of Edwards Lifesciences Co. (NYSE:EW)

Cambridge Trust Co. lessened its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 8.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,440 shares of the medical research company’s stock after selling 129 shares during the quarter. Cambridge Trust Co.’s holdings in Edwards Lifesciences were worth $110,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the stock. Castleview Partners LLC purchased a new position in Edwards Lifesciences in the 1st quarter worth approximately $25,000. Compass Wealth Management LLC purchased a new position in Edwards Lifesciences in the fourth quarter worth $31,000. Turtle Creek Wealth Advisors LLC bought a new position in Edwards Lifesciences in the fourth quarter valued at $34,000. Janiczek Wealth Management LLC raised its position in Edwards Lifesciences by 108.6% during the third quarter. Janiczek Wealth Management LLC now owns 582 shares of the medical research company’s stock valued at $40,000 after purchasing an additional 303 shares in the last quarter. Finally, Operose Advisors LLC raised its position in Edwards Lifesciences by 247.0% during the third quarter. Operose Advisors LLC now owns 635 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 452 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Catherine M. Szyman sold 27,000 shares of the business’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $85.62, for a total value of $2,311,740.00. Following the sale, the vice president now directly owns 34,814 shares of the company’s stock, valued at $2,980,774.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Edwards Lifesciences news, VP Jean-Luc M. Lemercier sold 14,400 shares of the company’s stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $92.32, for a total transaction of $1,329,408.00. Following the transaction, the vice president now owns 173,849 shares in the company, valued at approximately $16,049,739.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Catherine M. Szyman sold 27,000 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $85.62, for a total transaction of $2,311,740.00. Following the completion of the sale, the vice president now owns 34,814 shares of the company’s stock, valued at $2,980,774.68. The disclosure for this sale can be found here. Insiders have sold a total of 194,004 shares of company stock valued at $17,166,254 in the last ninety days. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Price Performance

EW opened at $85.94 on Friday. Edwards Lifesciences Co. has a 12-month low of $60.57 and a 12-month high of $96.12. The company has a market cap of $51.73 billion, a price-to-earnings ratio of 37.37, a price-to-earnings-growth ratio of 4.29 and a beta of 1.05. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09. The stock has a fifty day simple moving average of $90.15 and a two-hundred day simple moving average of $78.31.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.64. The company had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.50 billion. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. Edwards Lifesciences’s quarterly revenue was up 13.3% compared to the same quarter last year. During the same period last year, the business earned $0.64 EPS. Research analysts predict that Edwards Lifesciences Co. will post 2.76 earnings per share for the current fiscal year.

Analysts Set New Price Targets

EW has been the topic of several recent research reports. Morgan Stanley increased their price objective on Edwards Lifesciences from $95.00 to $103.00 and gave the company an “overweight” rating in a research report on Thursday, March 21st. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research report on Thursday, March 7th. StockNews.com cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Wednesday, March 20th. Royal Bank of Canada upped their price target on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the company an “outperform” rating in a report on Monday, April 15th. Finally, Truist Financial raised their price target on shares of Edwards Lifesciences from $78.00 to $84.00 and gave the stock a “buy” rating in a report on Friday, December 22nd. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $91.73.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.